Last updated: September 21, 2026
Treprostinil diolamine is the active pharmaceutical ingredient in United Therapeutics' Orenitram extended-release tablets, an oral prostacyclin analogue approved for pulmonary arterial hypertension (PAH). Orenitram occupies a differentiated position because it delivers treprostinil orally, avoiding the infusion equipment required for Remodulin and the inhalation devices used for Tyvaso.
The product has generated sustained growth for United Therapeutics, but its competitive position is constrained by the broader PAH market, where oral therapies such as selexipag, macitentan, tadalafil, and sildenafil compete for treatment sequencing and combination use. Formulation patents and method-of-use claims remain more important than the underlying treprostinil molecule, which is no longer commercially unique.
What is treprostinil diolamine and which drug contains it?
Treprostinil diolamine is the diolamine salt of treprostinil. The principal marketed product is Orenitram, an extended-release oral tablet developed and commercialized by United Therapeutics Corporation.
| Item |
Detail |
| Active ingredient |
Treprostinil diolamine |
| Brand |
Orenitram |
| Dosage form |
Extended-release oral tablets |
| Sponsor |
United Therapeutics Corporation |
| FDA application |
NDA 203496 |
| Original approval |
December 2013 |
| Indication |
Pulmonary arterial hypertension, WHO Group 1 |
| Administration |
Oral, two or three times daily depending on regimen |
| Related treprostinil products |
Remodulin injection and Tyvaso inhalation products |
| Primary market |
PAH, including functional class II-IV patients |
The FDA approved Orenitram to reduce disease progression and improve exercise capacity in adults with PAH. The prescribing information identifies treprostinil as a direct pulmonary and systemic arterial vasodilator and inhibitor of platelet aggregation.[1]
Orenitram is pharmacologically related to Remodulin and Tyvaso, but the commercial products are not interchangeable. Remodulin is parenteral treprostinil sodium, while Tyvaso is inhaled treprostinil. Orenitram uses the diolamine salt in an extended-release oral delivery system.
How large is the treprostinil diolamine market?
The relevant commercial market is the PAH prostacyclin-pathway market rather than the salt-specific treprostinil diolamine market. United Therapeutics does not generally report Orenitram revenue as a separate global pharmaceutical market category across all disclosures, but Orenitram is a material product in the company's portfolio.
The market has three layers:
- Oral prostacyclin-pathway treatment, led by Orenitram and Uptravi.
- Inhaled prostacyclin therapy, led by Tyvaso and generic or branded alternatives.
- Continuous infusion therapy, led by Remodulin and Flolan-class products.
Orenitram is most commercially exposed to Uptravi, marketed by Johnson & Johnson's Janssen, and to oral combination regimens involving endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
What drives Orenitram demand?
Orenitram demand is supported by several clinical and commercial factors:
- Patients who require prostacyclin-pathway treatment but are not candidates for continuous infusion.
- Patients seeking to avoid inhaled administration several times per day.
- Existing treprostinil users transitioning from parenteral or inhaled therapy.
- PAH centers using oral therapy earlier in treatment escalation.
- United Therapeutics' established relationships with specialty pharmacies and pulmonary hypertension centers.
Demand is limited by tolerability. Orenitram commonly causes headache, diarrhea, nausea, flushing, jaw pain, and other prostacyclin-related adverse events. Dose escalation must be individualized, and administration requires consistent timing with food under the product labeling.[1]
What is the financial trajectory for Orenitram?
Orenitram has been a growth product for United Therapeutics, although its growth rate is below that of Tyvaso, particularly after the launch and expansion of Tyvaso DPI.
United Therapeutics' annual reports identify Orenitram as one of the company's principal commercial products. Reported Orenitram revenue increased during the early 2020s as PAH treatment volumes expanded and the product gained adoption among patients seeking oral prostacyclin therapy.[2][3]
| Financial factor |
Effect on Orenitram |
| Prescription growth |
Supports steady top-line expansion |
| Net pricing |
Increases revenue but faces payer and specialty-pharmacy pressure |
| Tyvaso expansion |
Helps the franchise but can shift patients toward inhaled treprostinil |
| Uptravi competition |
Limits share gains in oral prostacyclin therapy |
| Manufacturing scale |
Supports high gross margins typical of specialty pharmaceuticals |
| Generic entry |
Would create the largest potential revenue shock |
| Reimbursement |
Depends on specialty pharmacy and commercial-plan coverage |
| Patient support |
Reduces treatment discontinuation and improves persistence |
United Therapeutics benefits from a portfolio structure in which the same PAH prescriber base can use Orenitram, Tyvaso, and Remodulin at different stages of treatment. This creates cross-selling opportunities, but it also creates internal substitution risk. A patient who moves from Orenitram to Tyvaso DPI may remain within the United Therapeutics franchise while reducing Orenitram revenue.
What is the revenue exposure to Orenitram?
Orenitram is smaller than the combined Tyvaso franchise but remains strategically important because it is an oral product with a different administration profile. Its commercial value is tied to:
- Recurring chronic use.
- High disease severity and specialist prescribing.
- Limited patient switching after successful dose titration.
- Specialty-pharmacy distribution.
- The absence of a clearly established, widely available generic substitute.
The product's financial trajectory is therefore more likely to show gradual erosion after loss of exclusivity rather than an immediate collapse, unless a generic entrant secures a substitutable formulation and broad payer acceptance.
What patents protect Orenitram and treprostinil diolamine?
Orenitram protection relies on formulation, release characteristics, salt composition, dosage strength, and methods of treating PAH. The treprostinil molecule itself has older composition-of-matter history and does not provide the same level of remaining exclusivity as the extended-release oral formulation.
The key patent families associated with Orenitram include extended-release treprostinil formulations and treatment methods. A principal U.S. patent publicly associated with the Orenitram formulation estate is U.S. Patent No. 8,598,227, which covers sustained-release treprostinil formulations and related pharmaceutical compositions.[4]
| Protection category |
Commercial relevance |
| Extended-release formulation |
Controls oral delivery profile and dosing frequency |
| Treprostinil diolamine composition |
Supports salt-specific formulation claims |
| Tablet manufacturing |
Can create process barriers for generic applicants |
| Dose-escalation methods |
May protect titration and treatment protocols |
| PAH treatment methods |
Can support Orange Book listing where statutory requirements are met |
| Pediatric extensions |
May add six months where granted |
| Regulatory exclusivity |
Applies separately from patent term |
Patent protection is more complex than a single expiration date because the product can have multiple listed patents with different expiry dates, terminal disclaimers, patent-term adjustments, and possible pediatric extensions.
When do Orenitram patents expire?
The earliest core formulation protection is generally associated with the late 2020s, while later-filed formulation and method patents may extend into the early 2030s. The practical loss-of-exclusivity date depends on:
- The latest valid Orange Book-listed patent.
- Whether an ANDA applicant makes a Paragraph IV certification.
- The outcome of infringement litigation.
- The scope of any settlement agreement.
- Whether later patents are found invalid, unenforceable, or not infringed.
- Any six-month pediatric exclusivity period.
The FDA Orange Book, rather than a commercial product page, is the controlling source for current listed patents and expiry information.[5]
What is the Orange Book status of Orenitram?
Orenitram is an FDA-approved prescription drug subject to the Hatch-Waxman framework. Its NDA and associated patent listings are relevant to abbreviated new drug application, or ANDA, applicants.
An ANDA applicant seeking approval for a generic extended-release treprostinil product may certify that listed patents are:
- Not infringed.
- Invalid.
- Unenforceable.
- Expired.
- Not subject to certification because the applicant is seeking approval after patent expiry.
A Paragraph IV certification can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman Act.[6]
The regulatory challenge is substantial because an applicant would need to demonstrate pharmaceutical equivalence and bioequivalence for an extended-release product with clinically meaningful exposure characteristics. A generic applicant may also need to address formulation differences, food effects, dose proportionality, and tablet release behavior.
Are there Paragraph IV challenges to treprostinil diolamine?
Publicly available information does not establish a broad, commercially active generic market for Orenitram comparable to older oral PAH medicines such as sildenafil or tadalafil. No widely marketed FDA-approved generic Orenitram substitute had displaced the branded product through the latest public regulatory and company disclosures reviewed for this analysis.
The absence of a marketed generic does not eliminate Paragraph IV risk. An ANDA applicant can challenge patents before commercial launch. The main possible challengers would include large generic companies with experience in complex oral dosage forms, specialty-pharmacy products, and controlled-release formulations.
The most important risk indicators are:
- An FDA Orange Book patent certification by an ANDA applicant.
- A Delaware or federal district court infringement complaint.
- A 30-month stay affecting ANDA approval.
- A settlement permitting an authorized or independent generic launch.
- FDA approval of a therapeutically equivalent product.
What formulation patents protect Orenitram?
The formulation estate is commercially important because oral treprostinil must provide controlled release while maintaining tolerability and predictable exposure.
Potentially valuable claim areas include:
- Treprostinil diolamine in a matrix tablet.
- Extended-release tablets with defined dissolution profiles.
- Multiple dosage strengths used in titration.
- Formulations designed for administration with food.
- Release profiles that reduce peak-related adverse effects.
- Manufacturing processes that produce consistent tablet performance.
A generic applicant could attempt a design-around by changing excipients, tablet architecture, release mechanism, or salt form. That approach would still require FDA approval and bioequivalence. A design-around may reduce patent infringement risk but increase development and regulatory risk.
What method-of-use patents cover treprostinil diolamine?
Method-of-use protection may cover treatment of PAH with oral extended-release treprostinil, dose escalation, conversion from other treprostinil products, and specific patient populations.
Method patents have narrower commercial value than formulation patents when physicians can prescribe an alternative product for the same disease. Their value increases when:
- The method is reflected in the FDA-approved label.
- The patent is listed in the Orange Book.
- The treatment protocol is routinely used in clinical practice.
- Substitution would expose a generic applicant to inducement-of-infringement risk.
Method-of-use claims are vulnerable if the patented method is not commercially necessary for prescribing the generic or if physicians routinely use the product outside the patented indication.
Which companies compete with Orenitram?
Uptravi versus Orenitram
Uptravi, marketed by Janssen, is the most direct branded competitor in oral prostacyclin-pathway therapy. It uses selexipag, a selective prostacyclin IP receptor agonist, while Orenitram is treprostinil itself.
| Factor |
Orenitram |
Uptravi |
| Active ingredient |
Treprostinil diolamine |
Selexipag |
| Mechanism |
Prostacyclin analogue |
IP receptor agonist |
| Administration |
Oral extended-release tablet |
Oral tablet |
| Sponsor |
United Therapeutics |
Janssen |
| Main advantage |
Direct treprostinil exposure without infusion or inhalation |
Oral dosing and strong specialist adoption |
| Main risk |
Prostacyclin-related tolerability and titration burden |
Competitive pricing and class substitution |
Tyvaso and Tyvaso DPI compete indirectly. Their inhaled delivery may be preferred where clinicians seek targeted pulmonary delivery or where oral therapy is insufficient. Remodulin competes at the severe end of disease but is also part of United Therapeutics' internal treatment ladder.
How strong is the Orenitram patent estate?
The estate is commercially meaningful but not invulnerable.
Strengths
- The active product uses a specialized extended-release formulation.
- The brand has multiple strengths and a defined titration pathway.
- Generic development requires more than simple immediate-release tablet replication.
- Specialty distribution and PAH-center prescribing create market-entry friction.
- Formulation and manufacturing claims can complicate design-around strategies.
Weaknesses
- Treprostinil is an established active ingredient.
- The core molecule is not a new chemical entity.
- Method-of-use patents may have limited blocking power.
- Generic applicants can challenge formulation claims through Paragraph IV litigation.
- The relevant market is clinically competitive, reducing the value of a single branded product's exclusivity.
The estate is stronger against an ordinary copy of the branded extended-release tablet than against a non-infringing formulation with a different release technology. The commercial outcome will depend on whether the generic can obtain therapeutic substitution and payer coverage, not only whether it obtains FDA approval.
What manufacturing and intellectual-property barriers affect generic entry?
Manufacturing barriers include:
- Consistent low-dose content uniformity.
- Controlled-release dissolution across multiple strengths.
- Reproducible food-effect performance.
- Stability of treprostinil diolamine in the tablet matrix.
- Scale-up of a process that meets FDA release specifications.
- Bioequivalence across the full dosing range.
Treprostinil is also a potent pharmacologically active compound. Manufacturing controls, worker safety, containment, and analytical validation increase development complexity relative to conventional high-volume oral generics.
What licensing deals affect treprostinil diolamine?
United Therapeutics is the principal commercial rights holder for Orenitram in the United States. The core Orenitram commercial strategy is internally integrated with United Therapeutics' Remodulin and Tyvaso portfolio.
No major third-party licensing transaction was identified as a primary driver of Orenitram's commercial economics in the public company disclosures reviewed. The more important strategic relationships are specialty-pharmacy, distribution, clinical-center, and reimbursement arrangements rather than an external license that transfers core Orenitram rights.
What litigation and settlement risks affect Orenitram?
The main litigation risk is a Hatch-Waxman action after a Paragraph IV certification. A lawsuit could delay approval for up to 30 months, subject to statutory exceptions and court outcomes.
Potential settlement structures include:
- A delayed generic entry date.
- An authorized generic arrangement.
- A license covering selected strengths or formulations.
- A covenant not to sue for a redesigned product.
- A settlement tied to patent expiry or pediatric exclusivity.
A settlement can preserve branded revenue while establishing a defined erosion date. It can also increase risk if the generic receives an early entry license before all commercially relevant patents expire.
What is the FDA regulatory status of treprostinil diolamine?
Orenitram is FDA-approved for adult patients with PAH, WHO Group 1, to reduce disease progression and improve exercise capacity.[1] It is a small-molecule drug, not a biologic, so biosimilar regulation does not apply.
The relevant regulatory pathway for competitors is an ANDA if the applicant can establish pharmaceutical equivalence and bioequivalence. A 505(b)(2) application is another possible pathway if the proposed product differs materially from the reference product or relies on additional clinical or pharmacokinetic evidence.
There is no biosimilar risk for Orenitram. The competitive threat is generic or hybrid small-molecule entry.
What generic launch scenarios exist for Orenitram?
| Scenario |
Timing |
Commercial effect |
| No ANDA challenge |
After final patent expiry |
Gradual generic entry risk |
| Paragraph IV filing with litigation |
Before patent expiry |
Branded protection during litigation; outcome-dependent |
| Court invalidates key formulation patent |
Potentially before expiry |
Accelerated generic entry and rapid price pressure |
| Settlement with licensed entry |
Agreed future date |
Predictable but material revenue erosion |
| Non-infringing 505(b)(2) product |
Regulatory-dependent |
Could bypass some ANDA-related barriers |
| Authorized generic |
Controlled by brand company |
Protects volume while reducing external generic share |
The most likely near-term risk is not biosimilar substitution but a delayed, litigation-driven generic event involving the extended-release formulation.
How does Orenitram compare with Tyvaso and Remodulin?
| Product |
Delivery |
Strategic role |
Main commercial risk |
| Orenitram |
Oral extended-release |
Avoids infusion and inhalation |
Uptravi competition and generic entry |
| Tyvaso |
Inhaled solution or DPI |
Inhaled prostacyclin therapy |
Device competition and adherence |
| Remodulin |
Continuous infusion or injection |
Advanced PAH and escalation therapy |
Administration burden and competing prostacyclins |
Tyvaso has become the main growth engine in United Therapeutics' PAH portfolio. Orenitram remains important because it addresses a separate administration preference and treatment stage. The portfolio reduces overall franchise risk but can cause product-level cannibalization.
What is the geographic coverage and international risk?
Orenitram's strongest commercial position is in the United States, where United Therapeutics controls the brand, specialty-pharmacy infrastructure, and regulatory strategy. International availability is more fragmented because PAH products may be commercialized under different names, through local partners, or under separate regulatory approvals.
Geographic risk includes:
- Different patent terms by jurisdiction.
- National reimbursement controls.
- Divergent approval standards for modified-release formulations.
- Local competition from generic treprostinil or alternative prostacyclin products.
- Currency and government-pricing pressure.
- Variations in PAH treatment guidelines.
U.S. Orange Book protection does not establish equivalent protection in Europe, Japan, Canada, or emerging markets. The product's international value must be assessed jurisdiction by jurisdiction.
Key Takeaways
- Treprostinil diolamine is the active ingredient in United Therapeutics' Orenitram extended-release tablets.
- Orenitram is an FDA-approved oral therapy for adult PAH patients.
- Its commercial differentiation is oral delivery without the infusion burden of Remodulin or the device burden of Tyvaso.
- Revenue growth has been supported by chronic specialty use and United Therapeutics' PAH franchise, although Tyvaso has become the stronger growth product.
- The core commercial protection is based on formulation, release, manufacturing, and method-of-use patents rather than new-chemical-entity exclusivity.
- The earliest meaningful patent risks are associated with the late 2020s, while later formulation and method claims may extend into the early 2030s.
- No biosimilar risk exists because treprostinil diolamine is a small molecule.
- The principal future threat is a Paragraph IV generic challenge involving the extended-release formulation.
- Generic entry would likely produce price and market-share erosion, but specialty prescribing, titration complexity, and manufacturing requirements could slow substitution.
- United Therapeutics' integrated Orenitram, Tyvaso, and Remodulin portfolio limits franchise-level risk but creates product-level cannibalization.
FAQs About Treprostinil Diolamine and Orenitram
Is treprostinil diolamine the same as treprostinil sodium?
No. Both deliver treprostinil, but Orenitram uses treprostinil diolamine in an oral extended-release tablet, while Remodulin uses treprostinil sodium in an injectable product.
Is Orenitram a biologic or a small-molecule drug?
Orenitram is a small-molecule drug. Competitors would pursue generic or 505(b)(2) pathways rather than biosimilar approval.
Can patients substitute Orenitram for Tyvaso?
No automatic substitution should be assumed. The products use different delivery systems, dosing schedules, and treatment protocols. Conversion requires clinical management.
Does Orenitram have orphan-drug exclusivity?
Orenitram's commercial protection primarily reflects its approved formulation and patent estate. Orphan-drug designation and exclusivity must be confirmed through the FDA's current product and designation records rather than inferred from PAH's rare-disease status.
What would most reduce Orenitram revenue?
The largest potential reduction would come from FDA approval and payer adoption of a therapeutically substitutable generic extended-release treprostinil product. A competing oral prostacyclin product with lower pricing could also pressure volume before full patent expiry.
References
- U.S. Food and Drug Administration. (2024). Orenitram (treprostinil) extended-release tablets: Prescribing information.
- United Therapeutics Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- United Therapeutics Corporation. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Patent No. 8,598,227. (2013). Sustained release formulations of treprostinil.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2017). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
